<p>Guardant Health（纳斯达克代码：GH - 获取免费报告）在周四向投资者发布的研究报告中，TD Cowen 分析师将其目标价格从 63.00 美元上调至 72.00 美元，Benzinga 报道。该公司目前对该股票给予 “买入” 评级。TD Cowen 的目标价格暗示该股票相较于之前的收盘价有 18.73% 的潜在上涨空间。</p>
<p>获取 <strong>Guardant Health</strong> 警报：</p>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>其他研究分析师也对该股票发布了报告。加拿大丰业银行将 Guardant Health 的目标价格从 57.00 美元上调至 60.00 美元，并在 7 月 31 日的报告中给予该股票 “行业跑赢大盘” 评级。古根海姆将 Guardant Health 的目标价格从 56.00 美元上调至 67.00 美元，并在周四的研究报告中给予该股票 “买入” 评级。富国银行在周一的研究报告中开始覆盖 Guardant Health 的股票。他们给予 “增持” 评级，并设定 72.00 美元的目标价格。威廉·布莱尔在周四的研究报告中重申了对 Guardant Health 的 “跑赢大盘” 评级。最后，Cowen 在周四的研究报告中重新发布了对 Guardant Health 的 “买入” 评级。一位分析师对该股票给予了强烈买入评级，22 位分析师给予了买入评级。根据 MarketBeat.com 的数据，Guardant Health 目前的平均评级为 “买入”，共识目标价格为 64.75 美元。</p>
<p><strong>获取我们对 Guardant Health 的最新股票分析</strong></p>
<h2>Guardant Health 股票表现</h2>
<ul>
<li>解读颠覆：凯西·伍德最新投资策略</li>
</ul>
<p>在周四的午盘交易中，纳斯达克：GH 上涨 2.97 美元，达到 60.64 美元。该股票交易量为 2,793,540 股，而其平均交易量为 2,400,886 股。该公司的 50 日移动平均线为 55.08 美元，200 日移动平均线为 48.55 美元。Guardant Health 的 12 个月低点为 20.14 美元，12 个月高点为 68.00 美元。该股票的市值为 75.6 亿美元，市盈率为-17.99，贝塔值为 1.46。</p>
<p>Guardant Health（纳斯达克代码：GH - 获取免费报告）最近在 7 月 30 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.44 美元，超出市场共识预期的-0.52 美元，超出幅度为 0.08 美元。该公司在本季度的收入为 2.3209 亿美元，而市场共识预期为 2.1119 亿美元。去年同期，该公司每股收益为-0.84 美元。与去年同期相比，该季度的收入增长了 31.0%。Guardant Health 已将其 2025 财年的指导目标设定为每股收益。分析师平均预测 Guardant Health 在当前财年将发布-2.9 的每股收益。</p>
<h2>Guardant Health 的内部买卖情况</h2>
<ul>
<li>3 只快速增长的股票分析师预计价格将翻倍</li>
</ul>
<p>在其他消息中，首席执行官 Helmy Eltoukhy 在 9 月 9 日的交易中出售了 300,000 股公司股票。股票以平均价格 59.45 美元出售，总价值为 17,835,000.00 美元。交易完成后，首席执行官直接持有公司 2,123,499 股，价值约为 126,242,015.55 美元。这代表其持股比例减少了 12.38%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席执行官 Amirali Talasaz 在 7 月 1 日的交易中出售了 100,000 股公司股票。该股票以平均价格 50.88 美元出售，总交易额为 5,088,000.00 美元。交易完成后，首席执行官持有公司 1,971,830 股，价值约为 100,326,710.40 美元。该交易使其持股比例减少了 4.83%。该销售的披露信息可在此处找到。内部人士在上个季度出售了价值 23,069,965 美元的 402,691 股公司股票。内部人士持有公司 6.10% 的股份。</p>
<h2>Guardant Health 的机构交易情况</h2>
<p>对冲基金最近增加或减少了在该公司的持股。IFP Advisors Inc 在第二季度将其在 Guardant Health 的持股增加了 120.1%。IFP Advisors Inc 目前持有 612 股公司股票，价值 33,000 美元，此前在该期间内增持了 334 股。Signaturefd LLC 在第二季度将其在 Guardant Health 的持股增加了 50.5%。Signaturefd LLC 目前持有 635 股公司股票，价值 33,000 美元，此前在该期间内增持了 213 股。Allworth Financial LP 在第二季度将其在 Guardant Health 的持股增加了 358.4%。Allworth Financial LP 目前持有 706 股公司股票，价值 37,000 美元，此前在该期间内增持了 552 股。FNY Investment Advisers LLC 在第二季度获得了 Guardant Health 的新头寸，价值约为 62,000 美元。最后，SVB Wealth LLC 在第一季度获得了 Guardant Health 的新头寸，价值约为 54,000 美元。92.60% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Guardant Health 公司简介</h2>
<p>（获取免费报告）</p>
<p>Guardant Health, Inc 是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 响应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，这是一个为临床和生物制药客户设计的集成软件解决方案，旨在将接受检测的患者与具有潜在相关临床研究的可操作性改变相连接；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，这是一个用于肿瘤演变和治疗耐药性研究的计算机模拟平台，适用于各种生物标志物驱动的癌症。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，而非 Guardant Health</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>Cintas 股票在动能增强时发出明确的买入信号</li>
<li>什么是支撑位？</li>
<li>美光的股价反弹尚未结束：MU $190 即将到来</li>
<li>高股息房地产投资信托：它们是理想的多元化方式吗？</li>
<li>为什么交易者在大幅反弹后加倍押注 SoundHound 股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
<p>在考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>TD Cowen 将 Guardant Health (NASDAQ:GH) 的目标股价从 63.00 美元上调至 72.00 美元，维持 “买入” 评级。这意味着相较于前一交易日收盘价有 18.73% 的上涨空间。其他分析师也提高了他们的目标价，苏格兰银行将其设定为 60.00 美元，古根海姆则为 67.00 美元。Guardant Health 的股票交易价格为 60.64 美元，市值为 75.6 亿美元。该公司报告了同比增长 31% 的收入，上一季度每股收益为（0.44 美元），超出预期。内部人士最近出售了部分股份，减少了他们的持股比例</p>

<p>Guardant Health (NASDAQ:GH - Get Free Report) had its price objective boosted by analysts at TD Cowen from $63.00 to $72.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock. TD Cowen's price objective suggests a potential upside of 18.73% from the stock's previous close.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克代码：GH - 获取免费报告）在周四向投资者发布的研究报告中，TD Cowen 分析师将其目标价格从 63.00 美元上调至 72.00 美元，Benzinga 报道。该公司目前对该股票给予 “买入” 评级。TD Cowen 的目标价格暗示该股票相较于之前的收盘价有 18.73% 的潜在上涨空间。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 警报：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>Other research analysts have also issued reports about the stock. Scotiabank upped their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the stock a &#34;sector outperform&#34; rating in a report on Thursday, July 31st. Guggenheim increased their price target on shares of Guardant Health from $56.00 to $67.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday. Wells Fargo &amp; Company assumed coverage on shares of Guardant Health in a research note on Monday. They issued an &#34;overweight&#34; rating and a $72.00 price target for the company. William Blair reiterated an &#34;outperform&#34; rating on shares of Guardant Health in a research note on Thursday. Finally, Cowen reissued a &#34;buy&#34; rating on shares of Guardant Health in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating and twenty-two have assigned a Buy rating to the stock. According to MarketBeat.com, Guardant Health presently has an average rating of &#34;Buy&#34; and a consensus target price of $64.75.</p>
<div class="lb-trans"><p>其他研究分析师也对该股票发布了报告。加拿大丰业银行将 Guardant Health 的目标价格从 57.00 美元上调至 60.00 美元，并在 7 月 31 日的报告中给予该股票 “行业跑赢大盘” 评级。古根海姆将 Guardant Health 的目标价格从 56.00 美元上调至 67.00 美元，并在周四的研究报告中给予该股票 “买入” 评级。富国银行在周一的研究报告中开始覆盖 Guardant Health 的股票。他们给予 “增持” 评级，并设定 72.00 美元的目标价格。威廉·布莱尔在周四的研究报告中重申了对 Guardant Health 的 “跑赢大盘” 评级。最后，Cowen 在周四的研究报告中重新发布了对 Guardant Health 的 “买入” 评级。一位分析师对该股票给予了强烈买入评级，22 位分析师给予了买入评级。根据 MarketBeat.com 的数据，Guardant Health 目前的平均评级为 “买入”，共识目标价格为 64.75 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Guardant Health 的最新股票分析</strong></p>
</div><h2>Guardant Health Stock Performance</h2>
<div class="lb-trans"><h2>Guardant Health 股票表现</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：凯西·伍德最新投资策略</li>
</ul>
</div><p>NASDAQ:GH traded up $2.97 during midday trading on Thursday, reaching $60.64. 2,793,540 shares of the stock traded hands, compared to its average volume of 2,400,886. The company has a fifty day moving average of $55.08 and a 200 day moving average of $48.55. Guardant Health has a 12 month low of $20.14 and a 12 month high of $68.00. The stock has a market capitalization of $7.56 billion, a P/E ratio of -17.99 and a beta of 1.46.</p>
<div class="lb-trans"><p>在周四的午盘交易中，纳斯达克：GH 上涨 2.97 美元，达到 60.64 美元。该股票交易量为 2,793,540 股，而其平均交易量为 2,400,886 股。该公司的 50 日移动平均线为 55.08 美元，200 日移动平均线为 48.55 美元。Guardant Health 的 12 个月低点为 20.14 美元，12 个月高点为 68.00 美元。该股票的市值为 75.6 亿美元，市盈率为-17.99，贝塔值为 1.46。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. During the same quarter last year, the company posted ($0.84) earnings per share. The firm's revenue for the quarter was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, analysts predict that Guardant Health will post -2.9 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克代码：GH - 获取免费报告）最近在 7 月 30 日发布了季度财报。该公司报告季度每股收益（EPS）为-0.44 美元，超出市场共识预期的-0.52 美元，超出幅度为 0.08 美元。该公司在本季度的收入为 2.3209 亿美元，而市场共识预期为 2.1119 亿美元。去年同期，该公司每股收益为-0.84 美元。与去年同期相比，该季度的收入增长了 31.0%。Guardant Health 已将其 2025 财年的指导目标设定为每股收益。分析师平均预测 Guardant Health 在当前财年将发布-2.9 的每股收益。</p>
</div><h2>Insider Buying and Selling at Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的内部买卖情况</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师预计价格将翻倍</li>
</ul>
</div><p>In other news, CEO Helmy Eltoukhy sold 300,000 shares of the company's stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer directly owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Amirali Talasaz sold 100,000 shares of the company's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the completion of the transaction, the chief executive officer owned 1,971,830 shares in the company, valued at approximately $100,326,710.40. The trade was a 4.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 402,691 shares of company stock worth $23,069,965 over the last quarter. Insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，首席执行官 Helmy Eltoukhy 在 9 月 9 日的交易中出售了 300,000 股公司股票。股票以平均价格 59.45 美元出售，总价值为 17,835,000.00 美元。交易完成后，首席执行官直接持有公司 2,123,499 股，价值约为 126,242,015.55 美元。这代表其持股比例减少了 12.38%。该交易已在向 SEC 提交的文件中披露，相关文件可通过 SEC 网站获取。此外，首席执行官 Amirali Talasaz 在 7 月 1 日的交易中出售了 100,000 股公司股票。该股票以平均价格 50.88 美元出售，总交易额为 5,088,000.00 美元。交易完成后，首席执行官持有公司 1,971,830 股，价值约为 100,326,710.40 美元。该交易使其持股比例减少了 4.83%。该销售的披露信息可在此处找到。内部人士在上个季度出售了价值 23,069,965 美元的 402,691 股公司股票。内部人士持有公司 6.10% 的股份。</p>
</div><h2>Institutional Trading of Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的机构交易情况</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the business. IFP Advisors Inc lifted its stake in Guardant Health by 120.1% in the second quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after acquiring an additional 334 shares during the period. Signaturefd LLC increased its holdings in Guardant Health by 50.5% in the 2nd quarter. Signaturefd LLC now owns 635 shares of the company's stock worth $33,000 after buying an additional 213 shares during the period. Allworth Financial LP increased its holdings in Guardant Health by 358.4% in the 2nd quarter. Allworth Financial LP now owns 706 shares of the company's stock worth $37,000 after buying an additional 552 shares during the period. FNY Investment Advisers LLC acquired a new position in Guardant Health in the 2nd quarter worth approximately $62,000. Finally, SVB Wealth LLC acquired a new position in Guardant Health in the 1st quarter worth approximately $54,000. 92.60% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对冲基金最近增加或减少了在该公司的持股。IFP Advisors Inc 在第二季度将其在 Guardant Health 的持股增加了 120.1%。IFP Advisors Inc 目前持有 612 股公司股票，价值 33,000 美元，此前在该期间内增持了 334 股。Signaturefd LLC 在第二季度将其在 Guardant Health 的持股增加了 50.5%。Signaturefd LLC 目前持有 635 股公司股票，价值 33,000 美元，此前在该期间内增持了 213 股。Allworth Financial LP 在第二季度将其在 Guardant Health 的持股增加了 358.4%。Allworth Financial LP 目前持有 706 股公司股票，价值 37,000 美元，此前在该期间内增持了 552 股。FNY Investment Advisers LLC 在第二季度获得了 Guardant Health 的新头寸，价值约为 62,000 美元。最后，SVB Wealth LLC 在第一季度获得了 Guardant Health 的新头寸，价值约为 54,000 美元。92.60% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 响应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，这是一个为临床和生物制药客户设计的集成软件解决方案，旨在将接受检测的患者与具有潜在相关临床研究的可操作性改变相连接；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，这是一个用于肿瘤演变和治疗耐药性研究的计算机模拟平台，适用于各种生物标志物驱动的癌症。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Cintas Stock Sends a Clear Buy Signal as Momentum Builds</li>
<li>What is a support level?</li>
<li>Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>Why Traders Are Doubling Down on SoundHound Stock After Big Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而非 Guardant Health</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>Cintas 股票在动能增强时发出明确的买入信号</li>
<li>什么是支撑位？</li>
<li>美光的股价反弹尚未结束：MU $190 即将到来</li>
<li>高股息房地产投资信托：它们是理想的多元化方式吗？</li>
<li>为什么交易者在大幅反弹后加倍押注 SoundHound 股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

TD Cowen 将 Guardant Health（纳斯达克代码：GH）的目标股价上调至 72.00 美元